8-K: United Therapeutics Settles Litigation with Liquidia

United Therapeutics Corporation has entered into a settlement agreement with Liquidia Technologies, Inc. to resolve ongoing litigation, including patent disputes and trade secret claims.

Summary

• United Therapeutics Corporation (UT) and Liquidia Technologies, Inc. (Liquidia) have reached a settlement agreement to resolve multiple ongoing legal disputes.
• Under the agreement, Liquidia will pay UT a total of $330.4 million, comprising an initial $185 million for past damages and $145.4 million for ongoing sales of Yutrepia for PH-ILD, payable in two installments.
• Liquidia will amend its Yutrepia drug application to remove the PH-ILD indication and cease marketing for this condition, focusing solely on Pulmonary Arterial Hypertension (PAH).
• The settlement includes mutual releases of claims related to the settled litigation, with exceptions for trade secret claims against a former Liquidia executive.
• UT will pay Liquidia $10 million to settle claims related to generic Remodulin launch and antitrust conduct.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as it resolves significant litigation and secures substantial financial compensation for United Therapeutics Corporation.

Positives

• Resolution of significant and costly litigation between United Therapeutics and Liquidia.
• United Therapeutics will receive a total of $330.4 million in settlement payments from Liquidia.
• Liquidia will cease marketing Yutrepia for PH-ILD, removing a competitive product from that specific indication.
• The settlement provides clarity and reduces future legal expenses and uncertainties for both companies.
• United States Court of Appeals for the Third Circuit affirmed summary judgment in UT's favor on antitrust claims.

Negatives

• United Therapeutics will pay $10 million to Liquidia as part of the settlement.
• The litigation has been ongoing, incurring significant legal costs for both parties.
• The settlement does not fully resolve trade secret claims against a former Liquidia executive.

Risks

• Liquidia's ability to make the required settlement payments.
• The timing and outcome of the FDA's review of Liquidia's labeling amendment.
• Potential disputes concerning the interpretation or enforceability of the settlement agreement.
• The possibility of future litigation if any terms of the settlement are breached.

Future Outlook

The settlement is expected to resolve pending litigation, with Liquidia ceasing promotion of Yutrepia for PH-ILD and focusing on PAH. United Therapeutics anticipates receiving substantial settlement payments. The forward-looking statements highlight risks related to Liquidia's performance, FDA review, and potential disputes over the agreement's terms.

Management Comments

• "UT v. Liquidia, a case filed by UT in the U.S. District Court for the District of Delaware, alleging that Liquidia's Yutrepia product infringes UT's U.S. Patent No. 11,826,327 (the 327 patent), which expires February 3, 2042, and covers improving exercise capacity in patients suffering from pulmonary hypertension associated with interstitial lung disease (PH-ILD) by inhaling treprostinil at specific doses."
• "UT v. Liquidia, a case filed in the U.S. District Court for the Middle District of North Carolina, alleging that Liquidia's Yutrepia product infringes UT's U.S. Patent No. 11,357,782 (the 782 patent), which expires May 14, 2027, and has claims directed to the treatment of pulmonary hypertension by administering a powder formulation of treprostinil via oral inhalation with a dry powder inhaler."
• "Liquidia v. UT, a case also filed in the U.S. District Court for the Middle District of North Carolina, alleging that UT's product, Tyvaso DPI, infringes Liquidia's U.S. Patent No. 10,898,494 (the 494 patent), which expires May 5, 2037, and has claims directed to the treatment of pulmonary hypertension by administering specified amounts of treprostinil via a dry powder inhaler in a specified number of breaths."
• "Trade Secrets Litigation, consisting of two separate cases brought by UT in North Carolina state court against Liquidia and a former Liquidia executive, Dr. Robert Roscigno, alleging the theft of UT's trade secrets and breach of Dr. Roscigno's employment agreement with UT."
• "Liquidia will pay to UT an aggregate of $330.4 million, consisting of: (a) $185 million, representing an estimate of damages for past sales of Yutrepia for PH-ILD, to be paid within 30 business days of the Settlement Agreement; and (b) $145.4 million, representing an agreed estimate of damages for continuing sales of Yutrepia to PH-ILD patients after execution of the Settlement Agreement, payable in two equal installments of $72.7 million each on or before February 1, 2027 and April 30, 2027."
• "Liquidia has agreed to immediately file with the U.S. Food and Drug Administration (FDA) an amendment to its new drug application for Yutrepia to remove the PH-ILD indication and references to PH-ILD from the products labeling, and to diligently and urgently pursue FDA approval of that amendment."
• "As part of the Settlement Agreement discussed above, Liquidia and UT agreed to provide for settlement of all claims in this litigation in exchange for a $10.0 million payment by UT to Liquidia, payable within 30 business days after execution of the Settlement Agreement."
• "On October 7, 2026, the Third Circuit entered a decision (a) affirming the grant of summary judgment in UT's favor on the antitrust and state unfair competition claims, recognizing UT's procompetitive justifications; (b) reversing the grant of summary judgment in Sandoz's favor as to liability on its breach of contract claim, vacating the November 1, 2024 judgment and damages award, and remanding the claim for further proceedings; and (c) reversing the grant of summary judgment in UT's favor on the tortious interference claim, and remanding that claim for further proceedings."

Industry Context

StockSavvy.ai notes that this settlement is a significant event in the pulmonary hypertension drug market. By resolving patent disputes and removing a competitor from the PH-ILD indication, United Therapeutics strengthens its market position for its own PH-ILD treatments like Tyvaso DPI. The substantial settlement payment reflects the perceived value and impact of the disputed patents and market exclusivity.

Legal Proceedings

• UT v. Liquidia (District of Delaware): Alleging infringement of UT's U.S. Patent No. 11,826,327 (327 patent) by Liquidia's Yutrepia product for PH-ILD.
• UT v. Liquidia (Middle District of North Carolina): Alleging infringement of UT's U.S. Patent No. 11,357,782 (782 patent) by Liquidia's Yutrepia product for pulmonary hypertension.
• Liquidia v. UT (Middle District of North Carolina): Alleging infringement of Liquidia's U.S. Patent No. 10,898,494 (494 patent) by UT's Tyvaso DPI product.
• Trade Secrets Litigation (North Carolina state court): UT alleging theft of trade secrets and breach of employment agreement by Liquidia and a former executive.
• RareGen, LLC (now Liquidia PAH, LLC) and Sandoz Inc. v. UT: Alleging anticompetitive conduct in connection with generic Remodulin launch, including antitrust and breach of contract claims.

Stakeholder Impact

• Shareholders of United Therapeutics: Positive impact due to resolution of litigation and significant financial inflow, reducing uncertainty.
• Shareholders of Liquidia: Mixed impact; resolution of litigation is positive, but the substantial payment and removal of a key indication represent a significant cost and strategic shift.
• Patients with PH-ILD: Will need to transition to alternative therapies as Yutrepia will no longer be indicated or promoted for this condition.
• Healthcare providers: Will need to adapt to new labeling and prescription requirements for Yutrepia.
• Payers: Will receive updated guidance to deny prior authorization requests for Yutrepia for PH-ILD.

Next Steps

• Liquidia to seek dismissal with prejudice of all settled litigation actions within ten days of receiving the $185 million payment.
• Liquidia to immediately file an amendment with the FDA to remove the PH-ILD indication from Yutrepia's labeling.
• Liquidia to cease marketing, advertising, and promotion of Yutrepia for PH-ILD.
• United Therapeutics to receive the $185 million payment within 30 business days of the Settlement Agreement.
• United Therapeutics to receive the first $72.7 million installment of the Prospective Infringement Liquidia Payment on or before February 1, 2027.
• United Therapeutics to receive the second $72.7 million installment of the Prospective Infringement Liquidia Payment on or before April 30, 2027.

Key Dates

Recommendation

The settlement resolves significant litigation, which is a positive for United Therapeutics, leading to substantial cash inflow and removal of a competitor from a specific indication. However, the company is also making a payment and the long-term impact on market dynamics requires further observation. For Liquidia, the financial burden and strategic shift are considerable. Therefore, a 'hold' recommendation allows for monitoring of the execution of the settlement and its market impact.

Keywords

settlement agreement, litigation, patent infringement, pulmonary hypertension, interstitial lung disease, Yutrepia, Tyvaso DPI, treprostinil